Literature DB >> 19561306

Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats.

Zhenghao Zhang1, Geeta Datta, Yun Zhang, Andrew P Miller, Paulina Mochon, Yiu-Fai Chen, John Chatham, G M Anantharamaiah, C Roger White.   

Abstract

Systemic inflammation induces a multiple organ dysfunction syndrome that contributes to morbidity and mortality in septic patients. Since increasing plasma apolipoprotein A-I (apoA-I) and HDL may reduce the complications of sepsis, we tested the hypothesis that the apoA-I mimetic peptide 4F confers similar protective effects in rats undergoing cecal ligation and puncture (CLP) injury. Male Sprague-Dawley rats were randomized to undergo CLP or sham surgery. IL-6 levels were significantly elevated in plasma by 6 h after CLP surgery compared with shams. In subsequent studies, CLP rats were further subdivided to receive vehicle or 4F (10 mg/kg) by intraperitoneal injection, 6 h after sepsis induction. Sham-operated rats received saline. Echocardiographic studies showed a reduction in left ventricular end-diastolic volume, stroke volume, and cardiac output (CO) 24 h after CLP surgery. These changes were associated with reduced blood volume and left ventricular filling pressure. 4F treatment improved blood volume status, increased CO, and reduced plasma IL-6 in CLP rats. Total cholesterol (TC) and HDL were 79 +/- 5 and 61 +/- 4 mg/dl, respectively, in sham rats. TC was significantly reduced in CLP rats (54 +/- 3 mg/dl) due to a reduction in HDL (26 +/- 3 mg/dl). 4F administration to CLP rats attenuated the reduction in TC (69 +/- 4 mg/dl) and HDL (41 +/- 3 mg/dl) and prevented sepsis-induced changes in HDL protein composition. Increased plasma HDL in 4F-treated CLP rats was associated with an improvement in CO and reduced mortality. It is proposed that protective effects of 4F are related to its ability to prevent the sepsis-induced reduction in plasma HDL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19561306      PMCID: PMC2724220          DOI: 10.1152/ajpheart.01232.2008

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  45 in total

1.  A sensitive and convenient method for lipoprotein profile analysis of individual mouse plasma samples.

Authors:  D W Garber; K R Kulkarni; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2000-06       Impact factor: 5.922

2.  Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.

Authors:  D C Angus; W T Linde-Zwirble; J Lidicker; G Clermont; J Carcillo; M R Pinsky
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

3.  Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide.

Authors:  G Datta; M Chaddha; S Hama; M Navab; A M Fogelman; D W Garber; V K Mishra; R M Epand; R F Epand; S Lund-Katz; M C Phillips; J P Segrest; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2001-07       Impact factor: 5.922

4.  Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol.

Authors:  Mohamad Navab; G M Anantharamaiah; Susan Hama; David W Garber; Manjula Chaddha; Greg Hough; Roger Lallone; Alan M Fogelman
Journal:  Circulation       Date:  2002-01-22       Impact factor: 29.690

Review 5.  HDL and the inflammatory response induced by LDL-derived oxidized phospholipids.

Authors:  M Navab; J A Berliner; G Subbanagounder; S Hama; A J Lusis; L W Castellani; S Reddy; D Shih; W Shi; A D Watson; B J Van Lenten; D Vora; A M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-04       Impact factor: 8.311

6.  LDL- is a lipid hydroperoxide-enriched circulating lipoprotein.

Authors:  A Sevanian; G Bittolo-Bon; G Cazzolato; H Hodis; J Hwang; A Zamburlini; M Maiorino; F Ursini
Journal:  J Lipid Res       Date:  1997-03       Impact factor: 5.922

7.  Splenic denervation worsens lipopolysaccharide-induced hypotension, hemoconcentration, and hypovolemia.

Authors:  P S Andrew; S Kaufman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-05       Impact factor: 3.619

8.  ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response.

Authors:  S Barlage; D Fröhlich; A Böttcher; M Jauhiainen; H P Müller; F Noetzel; G Rothe; C Schütt; R P Linke; K J Lackner; C Ehnholm; G Schmitz
Journal:  J Lipid Res       Date:  2001-02       Impact factor: 5.922

9.  Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice.

Authors:  Uwe J F Tietge; Cyrille Maugeais; Sissel Lund-Katz; David Grass; Frederick C deBeer; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-07-01       Impact factor: 8.311

10.  Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days.

Authors:  Daniel G Remick; Gerald R Bolgos; Javed Siddiqui; Jungsoon Shin; Jean A Nemzek
Journal:  Shock       Date:  2002-06       Impact factor: 3.454

View more
  31 in total

Review 1.  Crosstalk between reverse cholesterol transport and innate immunity.

Authors:  Kathleen M Azzam; Michael B Fessler
Journal:  Trends Endocrinol Metab       Date:  2012-03-10       Impact factor: 12.015

2.  The role of HDL in innate immunity.

Authors:  Kenneth R Feingold; Carl Grunfeld
Journal:  J Lipid Res       Date:  2010-10-13       Impact factor: 5.922

3.  Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer.

Authors:  Feng Su; Kathy R Kozak; Satoshi Imaizumi; Feng Gao; Malaika W Amneus; Victor Grijalva; Carey Ng; Alan Wagner; Greg Hough; Gina Farias-Eisner; G M Anantharamaiah; Brian J Van Lenten; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

4.  High density lipoprotein protects against polymicrobe-induced sepsis in mice.

Authors:  Ling Guo; Junting Ai; Zhong Zheng; Deborah A Howatt; Alan Daugherty; Bin Huang; Xiang-An Li
Journal:  J Biol Chem       Date:  2013-05-08       Impact factor: 5.157

Review 5.  HDL apolipoprotein-related peptides in the treatment of atherosclerosis and other inflammatory disorders.

Authors:  G S Getz; G D Wool; C A Reardon
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 6.  Biological properties of apolipoprotein a-I mimetic peptides.

Authors:  Godfrey S Getz; Geoffrey D Wool; Catherine A Reardon
Journal:  Curr Atheroscler Rep       Date:  2010-03       Impact factor: 5.113

Review 7.  High-density lipoprotein mimetics: promises and challenges.

Authors:  Dmitri Sviridov; Alan T Remaley
Journal:  Biochem J       Date:  2015-12-15       Impact factor: 3.857

8.  Mild hypercholesterolemia blunts the proinflammatory and prothrombotic effects of hypertension on the cerebral microcirculation.

Authors:  Stephen F Rodrigues; Shantel A Vital; D Neil Granger
Journal:  J Cereb Blood Flow Metab       Date:  2013-01-02       Impact factor: 6.200

9.  Regulation of pattern recognition receptors by the apolipoprotein A-I mimetic peptide 4F.

Authors:  C Roger White; Lesley E Smythies; David K Crossman; Mayakonda N Palgunachari; G M Anantharamaiah; Geeta Datta
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09-13       Impact factor: 8.311

Review 10.  HDL as a biomarker, potential therapeutic target, and therapy.

Authors:  Mohamad Navab; G M Anantharamaiah; Srinivasa T Reddy; Brian J Van Lenten; Alan M Fogelman
Journal:  Diabetes       Date:  2009-12       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.